Skip to content
DataLookout
Menu

NCT07296328

Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Apr 1, 2027 to Sep 30, 2027 Show 6 more changesShow less
    • Recruitment opened
    • Start date changed from estimate of Jan 15, 2026 to May 7, 2026
    • Eligibility criteria expanded, about 44 words
    • Primary endpoints: details revised at 1 of 5 entries
    • Secondary endpoints: details revised at 5 of 5 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in Stuttering Severity Instrument - 4th Edition (SSI-4) total score
Timeframe: Week 4, Week 12
Change in frequency subcomponent score of the SSI-4
Timeframe: Week 4, Week 12
Change in duration subcomponent score of the SSI-4
Timeframe: Week 4, Week 12
Change in physical concomitants subcomponent score of the SSI-4
Timeframe: Week 4, Week 12
Change in Overall Assessment of the Speaker's Experience of Stuttering - Adults (OASES-A) score
Timeframe: Week 4, Week 12

Secondary (5)

Change in self-reported stuttering severity Wright and Ayre Stuttering Self-Rating Profile (WASSP) score
Change in the Brief Version of the Unhelpful Thoughts and Beliefs About Stuttering Scales (UTBAS-6) total score
Change in Brief Fear of Negative Evaluation Scale (BFNE-S) total score
Change in the Social Interaction Anxiety Scale (SIAS) score
Change in Stuttering Anticipation Scale (SAS) score

Arms and interventions

Adult stutterersExperimental

Participation will occur over an 8-week, 10-session period. Six sessions speech therapy; one preparatory therapy session prior to the drug administration session; one 8-hour drug administration session (25 mg of psilocybin); two follow-up therapy sessions following the drug administration session.

Drugs: Psilocybin

Behavioral: Speech therapy

Sites

1 site in 1 country

  • NYU Langone HealthNew York, New York, United States